









Markets
/
Stocks
/
nasdaq-lsta
/

Lisata Therapeutics Inc

LSTA

2.330USD

-0.060-2.51%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

20.10MMarket Cap

LossP/E TTM



Lisata Therapeutics Inc

2.330

-0.060-2.51%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

155 / 506

Overall Ranking

265 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

20.667

Target Price

+764.71%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to penetrate solid tumors. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (TME). It is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors. Its CD34+ is a cell therapy technology was targeting an array of diseases, among them, critical limb ischemia, coronary microvascular dysfunction, and diabetic kidney disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.00M.

Fairly Valued

The company’s latest PE is -1.04, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.52M shares, decreasing 2.59% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 254.18K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.77, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.77

Change



Financials

9.39

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

2.18

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.07, which is -63.12% below the recent high of -0.40 and -9.31% above the recent low of -1.17.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 155/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Lisata Therapeutics Inc is 15.00, with a high of 32.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

20.667

Target Price

+764.71%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Lisata Therapeutics Inc

LSTA

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.27, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.66 and the support level at 2.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.27

Change

-0.18

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.047

Neutral

RSI(14)

48.787

Neutral

STOCH(KDJ)(9,3,3)

71.035

Neutral

ATR(14)

0.167

Low Volatility

CCI(14)

126.366

Buy

Williams %R

28.177

Buy

TRIX(12,20)

-0.564

Sell

StochRSI(14)

80.191

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.284

Buy

MA10

2.252

Buy

MA20

2.306

Buy

MA50

2.489

Sell

MA100

2.517

Sell

MA200

2.567

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 29.29%, representing a quarter-over-quarter decrease of 3.94%. The largest institutional shareholder is The Vanguard, holding a total of 254.18K shares, representing 2.90% of shares outstanding, with 30.77% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Ruoslahti (Erkki)

1.10M

-6.62%

Mazzo (David J)

264.69K

+3.26%

The Vanguard Group, Inc.

Star Investors

254.18K

+36.39%

BML Capital Management LLC

216.85K

-23.82%

Renaissance Technologies LLC

Star Investors

102.72K

+1.38%

Buck (Kristen K)

79.79K

Geode Capital Management, L.L.C.

60.53K

+8.29%

BlackRock Institutional Trust Company, N.A.

54.86K

-2.06%

Azab (Mohammad)

52.28K

+23.92%

Klosk (Steven Mark)

49.57K

+8.05%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.24, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.02. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.